Clinical Trial Update: A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study assessing uprifosbuvir and ruzasvir in participants with moderate to severe hepatic impairment completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ruzasvir (ruzasvir)
• Uprifosbuvir (uprifosbuvir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 1 | Status: COMPLETED | Results posted: 2018-09-17